Methyl (2S,4S)-1-benzyl-4-[(tert-butyldimethylsilyl)oxy]pyrrolidine-2-carboxylate, a protected trans-4-hydroxy-L-proline building block, is employed across asymmetric syntheses where orthogonal deprotection, high enantiomeric fidelity, and minimal racemization at C-2 are non-negotiable. The compound—supplied as a colourless to pale-yellow oil with a relative molecular mass of 379.57 g·mol⁻¹—exhibits a characteristic specific rotation [α]²⁰D in the range −20° to −25° (c 1.0, CHCl₃). On a preparative scale, the substance has been incorporated into dipeptide isosteres and conformationally constrained pyrrolidine scaffolds for protease inhibitor discovery without detectable C-α epimerisation during coupling steps, as verified by 1H NMR of the derived Mosher amides. Routine characterization relies on spectral data that align with published assignments: the 13C NMR spectrum displays the carbonyl resonance of the methyl ester at ~172.4 ppm (CDCl₃) and the TBS quaternary carbon at ~18.1 ppm. The N‑benzyl benzylic protons appear as an AB quartet near 3.63 and 3.93 ppm in the 1H spectrum, confirming the absence of N‑alkylation side-products that occasionally contaminate batches produced via reductive amination routes under unoptimised stoichiometry.
How Does the (2S,4S) Configuration Influence Pharmacophoric Conformation and Synthetic Compatibility?
The (2S,4S) absolute stereochemistry defines a trans relationship between the carboxymethyl substituent at C‑2 and the silyloxy group at C‑4, enforcing a Cγ-exo or Cγ-endo envelope conformation of the pyrrolidine ring in solution. This arrangement distances the bulky TBS‑protected oxygen from the N‑benzyl group and mitigates 1,3‑allylic-type steric interactions that would otherwise attenuate nucleophilic substitution at the α‑carbon of the ester enolate. In contrast, the cis‑(2S,4R) diastereomer—often used as a building block for collagen-peptide mimics—places the silyloxy group syn to the ester, resulting in a narrower dihedral angle between the C-4 substituent and the C-2 carbonyl and consequently a higher propensity for β‑elimination of the protected hydroxyl during base‑mediated alkylations. This difference has been quantified in model enolate trapping experiments: under LiHMDS in THF at −78 °C, the (2S,4S) derivative yields ≤2% desilylated by‑product by reversed‑phase area‑count HPLC, whereas the (2S,4R) epimer generates 12–18% of the corresponding hydroxy‑free pyrrolidine, attributed to anchimeric assistance from the cis‑oriented ester enolate oxygen during fluoride‑catalyzed desilylation. Such disparity renders the (2S,4S) form the preferred stereoisomer for enolate‑based cyclisations and aldol‑type additions where TBS persistence is critical.
Purity Certification and Trace-Level Impurity Profiling
Lot‑release specifications are built around a combination of chromatographic and titrimetric data anchored to pharmacopoeial or equivalent consensus methods. Purity by HPLC is determined according to USP <621> on a 150 × 4.6 mm C18 column (5 µm) with a water‑acetonitrile gradient containing 0.1% trifluoroacetic acid; the target area‑percent at 210 nm is ≥96.0%. Enantiomeric excess is resolved via normal‑phase chiral HPLC on a Chiralpak IA column (250 × 4.6 mm, 5 µm) using n‑hexane/2‑propanol (98:2) at 1.0 mL·min⁻¹, referenced against a racemic standard produced by non‑stereoselective silylation of an authentic mixture of trans‑ and cis‑4‑hydroxyproline methyl ester benzyl derivatives. The acceptance criterion is ≥99.0% enantiomeric excess, with the minor (2R,4R) antipode eluting prior to the main peak. Water content, controlled to ≤0.2% w/w by coulometric Karl Fischer titration compliant with ASTM E203-16, is critical because residual moisture promotes slow silyl‑ether hydrolysis—observable as a rising hydroxyl impurity in samples stored above −15 °C in non‑airtight containers. Batch‑identity is substantiated by 1H‑ and 13C‑NMR, IR (C=O stretch at ~1740 cm⁻¹), and high‑resolution mass spectrometry with an error tolerance of ≤3 ppm for the [M+H]+ ion (m/z calculated 380.2258). A cumulative test‑data table accompanies each shipment:
| Parameter | Method | Specification | Observed (Lot F24‑178) |
|---|---|---|---|
| Purity (HPLC, 210 nm) | USP <621>, Area% | ≥ 96.0% | 97.8% |
| Enantiomeric excess | Chiral HPLC (Chiralpak IA) | ≥ 99.0% | 99.6% |
| Water (KF) | ASTM E203-16 | ≤ 0.2% | 0.08% |
| Specific rotation [α]²⁰D (c 1.0, CHCl₃) | USP <781> | −20° to −25° | −22.3° |
| Residual TBSCl | 1H NMR (δ 0.90 ppm) | Not detected | Not detected |
When TBS Ether Selection Intersects with N‑Benzyl Cleavage Orthogonality
The choice of the tert‑butyldimethylsilyl protecting group, rather than the bulkier tert‑butyldiphenylsilyl (TBDPS) or acid‑labile trimethylsilyl (TMS) ethers, is dictated by a narrow processing window where the N‑benzyl group must be preserved during hydroxyl liberation. Removal of the benzyl substituent by catalytic hydrogenolysis—typically Pd/C or Pd(OH)₂/C under 1–4 bar H₂ in ethanol or ethyl acetate—proceeds at room temperature without affecting the TBS ether, as verified by 1H NMR surveillance at 24‑hour intervals; no desilylated secondary amine is detected. TBDPS, while more stable under acidic conditions, presents a practical complication: its steric encumbrance retards the rate of ester hydrolysis at C‑2 when a subsequent carboxylic acid intermediate is required for amide coupling. Lithium hydroxide‑mediated saponification of methyl (2S,4S)-1-benzyl-4-(TBSO)pyrrolidine-2-carboxylate reaches >98% conversion within 3 hours in THF/water (3:1) at 0 °C, whereas the corresponding TBDPS derivative requires 12–18 hours and yields 5–7% of a C‑2 epimerised acid under identical conditions, as quantified by chiral HPLC of the re‑esterified product. The TBS group is therefore the optimum balance between orthogonal stability and downstream processing speed. Cleavage is achieved with tetra‑n‑butylammonium fluoride (TBAF) in THF or, in total‑synthesis sequences where fluoride salts complicate purification, with HF‑pyridine in THF at 0 °C. Published data for the direct comparison of all three silyl ethers under peptide coupling conditions is limited, but internal screening has confirmed that HCTU‑mediated amidation with N‑methylmorpholine in DMF proceeds to 94% conversion for the TBS substrate versus 82% for the TBDPS analogue, attributed to attenuated steric shielding of the activated ester intermediate.
Manufacturing campaigns at 100‑gram scale have revealed a subtle batch‑to‑batch variability linked to the sodium borohydride reduction step of the imine precursor. If the nitrile or amidine intermediate generated during reductive amination of 4‑oxoproline ester with benzylamine is not quenched with careful pH control (pH 4–5 before extraction), a benzylamide impurity (2–3% area) forms and cannot be easily separated by distillation; it co‑elutes with the product on silica gel. Optimal protocols employ NaBH(OAc)₃ in dichloromethane with acetic acid (1.5 equiv.) at 0–5 °C, which suppresses the amide side‑product to <0.3%. The purified product is packaged under argon in amber glass vials fitted with PTFE‑lined caps and shipped on wet ice to maintain a core temperature below 8 °C during transit, preventing the formation of a ring‑opened by‑product that has been observed when the material is stored for more than 72 hours at 25 °C in the presence of ambient CO₂. Storage at −20 ± 5 °C in a desiccated environment preserves the original purity profile for 12 months, confirmed by accelerated stability testing at 40 °C/75% RH where the TBS ether shows <2% degradation over 30 days, as per a stability‑indicating HPLC method validated for specificity per ICH Q2(R1) guidelines.
Comparative Orthogonality of N‑Protecting Groups: Benzyl versus Carbamate
A practical advantage of the N‑benzyl variant over the more common N‑Boc‑4‑(TBSO)‑L‑proline methyl ester lies in the ability to perform strongly acidic transformations on the pyrrolidine nitrogen without premature loss of the N‑masking group. The benzyl group withstands trifluoroacetic acid (TFA) solutions up to 20% (v/v) in dichloromethane for at least 4 hours at 23 °C, whereas Boc‑protected analogues are quantitatively deprotected within 10 minutes under the same conditions. This difference is exploited when the substrate must first undergo acid‑catalyzed acetal formation at the C‑2 ester — a scenario encountered in the synthesis of spiro‑pyrrolidine glycomimetics. Here, the benzyl‑TBS combination permits sequential Lewis acid activation (e.g., BF₃·OEt₂) for O‑glycosylation at C‑4 after TBAF deprotection, leaving the N‑benzyl intact for a late‑stage hydrogenolytic assembly of a free secondary amine. Detailed deprotection conditions and their intersect with TBS stability are summarised below.
| N‑Protecting Group | Removal Conditions | TBS Stability Under Those Conditions | Residual TBS After Removal Step (HPLC Area%, 210 nm) |
|---|---|---|---|
| Benzyl | H₂, 10% Pd/C, EtOH, 1 atm, 23 °C, 12 h | Stable | 98.5% |
| Benzyl | 20% TFA/CH₂Cl₂, 23 °C, 4 h | Loss <1% | 99.2% |
| Boc | 20% TFA/CH₂Cl₂, 23 °C, 10 min | Partial desilylation (8–12%) | 88–92% |
| Cbz | H₂, Pd/C, EtOH | Stable | 98.0% |
| Fmoc | 20% piperidine/DMF, 23 °C, 30 min | Stable | 99.0% |
When compared with the Cbz‑protected analogue, the benzyl derivative holds a synthetic‑efficiency advantage in the final global deprotection step: both can be removed simultaneously with the TBS group under HBr/HOAc conditions; however, Cbz requires a more forcing acidic medium that can lead to benzyl ester cleavage at C‑2 if a carboxylic acid is already present. Published data indicate that methyl esters survive hydrobromic acid in acetic acid at 0 °C for 1 hour with <5% ester hydrolysis, while benzyl esters degrade completely, making the methyl ester‑N‑benzyl‑TBS architecture the most flexible for multistep sequences. Laboratory‑scale experience confirms that the compound can be substituted directly into solid‑phase peptide synthesis protocols: after Fmoc‑SPPS on a Wang resin, the free N‑benzyl pyrrolidine obtained after Fmoc cleavage can be coupled to a deprotected peptide acid using PyBOP and DIEA in DMF without detectable epimerisation at the pyrrolidine C‑2, verified by analytical HPLC of the diastereomeric peptide product.
Substrates with the N‑benzyl‑TBS‑O pattern also display defined crystallisation behaviour for the derived hydrochloride salt. Addition of 1.0 equiv. of HCl (4 M in dioxane) to the free base isolated after hydrogenolysis yields a non‑hygroscopic solid that can be stored at room temperature in a desiccator, unlike the corresponding TBDPS‑substituted salt, which remains an oil. This physical form advantage simplifies pilot‑plant handling and accurate weighing in multi‑gram parallel synthesis arrays. The manufacturer’s certificate of analysis provides the salt’s chloride content by argentometric titration (USP <221>) as an orthogonal identity check.
